Heparin-lnduced Thrombocytopenia, Thrombosis, and Hemorrhage

Abstract

Sixty-two patients with a heparin-induced thrombocytopenia are reported. Clinical manifestations of this disorder include hemorrhage or, more frequently, thromboembolic events in patients receiving heparin. Laboratory testing has revealed a falling platelet count, increased resistance to heparin, and aggregation of platelets by the patient's plasma when heparin is added. Immunologic testing has demonstrated the presence of a heparin-dependent platelet membrane antibody. The 20 deaths, 52 hemorrhagic and thromboembolic complications, and 21 surgical procedures to manage the complications confirm the seriousness of the disorder. Specific risk factors have not been identified; therefore, all patients receiving heparin should be monitored. If the platelet count falls to less than 100,000/mm3, while the patient is receiving heparin, platelet aggregation testing, using the patient's plasma, is indicated. Management consists of cessation of heparin, platelet anti-aggregating agents, and alternate forms of anticoagulation when indicated.

In-Situ Forming Biomimetic Hydrogels for Tissue Regeneration

“…Besides, the use of hparin can efficiently control the release rate of bFGF. However, large quantity use of heparin induces side effects such as thrombocytopenia, thrombosis, and hemorrhage (Silver et al, 1983). To solve this problem, Prestwich et al proposed an in-situ forming glycosaminoglycan (GAG) hydrogel based on hyaluronan (HA) and chondroitin sulfate (CS) (Cai et al, 2005).…”

Streptokinase Therapy of Pulmonary Emboli With Heparin-Associated Thrombocytopenia

“…It has been postulated that activated circulating eosinophils cause endovascular damage in this disorder through release of their granule contents, which are toxic to endothelial cells. 6 We have recently encountered a patient with chronic eosinophilia and thromboangiitis obliterans. A potential relationship between these two abnormalities was sug¬ gested by the finding of several thrombosed arteries infil¬ trated with eosinophils.…”

Pulmonary Embolism due to Heparin-Induced Thrombocytopenia (HIT): A Case Report of an 11-year-old Child Undergoing Scoliosis Surgery and Literature Review

“…HIT-II should be treated with immediate discontinuation of all heparin products and initiation of an alternative non-heparin anticoagulant [11]. HIT morbidity and mortality rates of 61% and 22.5% have been respectively reported in adults [21]. HIT occurrence in children varies between 1.5% (neonatal intensive care unit) [22] and 2.3% (pediatric intensive care unit) [23].…”